NASDAQ · SNPX
Healthcare · Biotechnology
$24.55
Up+$1.81 (+29.86%)
Updated Aug 6, 2026, 5:43 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
SNPX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning SNPX.
SNPX research
Company profile and research snapshot.
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 11, 2024 | Maxim Group | Buy | — |
| Dec 19, 2022 | Maxim Group | Hold | — |
| Apr 12, 2022 | Maxim Group | Buy | — |
No generated briefing is available yet.
prnewswire.com · Nov 18, 2025
NEW YORK, Nov. 18, 2025 /PRNewswire/ -- Tradr ETFs, a provider of ETFs designed for sophisticated investors and professional traders, today announced that options trading is now available on its four newest leveraged ETFs, which were launched on November 13
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SNPX.
No results
No recent SID articles mention SNPX.
